3.59%
13.07%
-0.57%
-41.75%
-28.22%
-80.14%
-91.71%
AI Spotlight on HRTX
Company Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs.The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy.The company was formerly known as A.P. Pharma, Inc.and changed its name to Heron Therapeutics, Inc.
in January 2014.Heron Therapeutics, Inc.was founded in 1983 and is headquartered in San Diego, California.
Market Data
| Last Price | 1.73 |
| Change Percentage | 3.59% |
| Open | 1.68 |
| Previous Close | 1.67 |
| Market Cap ( Millions) | 263 |
| Volume | 1039721 |
| Year High | 3.93 |
| Year Low | 1.04 |
| M A 50 | 1.51 |
| M A 200 | 2.28 |
Financial Ratios
| FCF Yield | -3.65% |
| Dividend Yield | 0.00% |
| ROE | 76.79% |
| Debt / Equity | -445.56% |
| Net Debt / EBIDTA | -686.59% |
| Price To Book | -6.61 |
| Price Earnings Ratio | -9.45 |
| Price To FCF | -27.37 |
| Price To sales | 1.79 |
| EV / EBITDA | -18.71 |
News
- Dec -23 - Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
- Dec -04 - Relief For Heron Therapeutics After The Court Win On Cinvanti
- Dec -03 - U.S. District Court Upholds Validity of CINVANTI® Patents
- Nov -12 - Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
- Nov -12 - Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- Nov -12 - Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
- Nov -12 - Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
- Nov -07 - Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
- Nov -04 - Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
- Oct -29 - Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
- Oct -10 - Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
- Sep -25 - Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Sep -03 - Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
- Aug -07 - Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Aug -06 - Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
- Aug -06 - Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
- Jul -30 - Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
- Jul -15 - Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
- Jul -11 - Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
- Jul -11 - New Strong Buy Stocks for July 11th
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapeutic Innovations
Expected Growth : 10.33 %
What the company do ?
Heron Therapeutics' Therapeutic Innovations involve developing novel, patient-focused solutions to address unmet medical needs, improving patient outcomes and quality of life.
Why we expect these perspectives ?
Heron Therapeutics' 10.33% growth is driven by increasing adoption of its therapeutic innovations, particularly in pain management and oncology care. Strong demand for its flagship product, Sustol, and expanding pipeline of novel treatments contribute to the growth. Additionally, strategic partnerships and collaborations with healthcare providers and research institutions further fuel the company's expansion.
Heron Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| SUSTOL | SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. |
| CINVANTI | CINVANTI is a neurokinin-1 (NK-1) receptor antagonist indicated in adults, in combination with other antiemetics, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. |
| HTX-019 | HTX-019 is a proprietary, extended-release formulation of aprepitant, a neurokinin-1 (NK-1) receptor antagonist, being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). |
Heron Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
Heron Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for pain management and opioid addiction.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of Heron Therapeutics, Inc.'s products and the lack of alternative options for patients.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's dependence on a few key suppliers.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and significant capital requirements.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of established competitors in the pain management and opioid addiction markets, leading to intense competition for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 123.78% |
| Debt Cost | 3.95% |
| Equity Weight | -23.78% |
| Equity Cost | 12.62% |
| WACC | 1.88% |
| Leverage | -520.50% |
Heron Therapeutics, Inc. : Quality Control
Heron Therapeutics, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CPRX | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, … |
| MDXG | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts … |
| LQDA | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
| URGN | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Catalyst Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
MiMedx
A-Score
1-Year Total Return ->
🥉
Heron Therapeutics
A-Score
1-Year Total Return ->
4
Armata Pharmaceuticals
A-Score
1-Year Total Return ->
5
UroGen Pharma
A-Score
1-Year Total Return ->
6
